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FN14 has been implicated in many intracellular signaling pathways, and GRP94 is a 
well-known endoplasmic reticulum protein regulated by glucose. Recently, both have 
been associated with metastasis progression in breast cancer patients. We studied the 
usefulness of FN14 and GRP94 expression to stratify breast cancer patients accord-
ing their risk of brain metastasis (BrM) progression. We analyzed FN14 and GRP94 
by immunohistochemistry in a retrospective multicenter study using tissue microarrays 
from 208 patients with breast carcinomas, of whom 52 had developed BrM. Clinical 
and pathological characteristics and biomarkers expression in Luminal and non- 
Luminal patients were analyzed using a multivariate logistic regression model adjusted for 
covariates, and brain metastasis-free survival (BrMFS) was estimated using the Kaplan–
Meier method and the Cox proportional hazards model. FN14 expression was associated 
with BrM progression mainly in Luminal breast cancer patients with a sensitivity (53.85%) 
and specificity (89.60%) similar to Her2 expression (46.15 and 89.84%, respectively). 
Moreover, the likelihood to develop BrM in FN14-positive Luminal carcinomas increased 
36.70-fold (3.65–368.25, p = 0.002). Furthermore, the worst prognostic factor for BrMFS 
in patients with Luminal carcinomas was FN14 overexpression (HR =  8.25; 95% CI: 
2.77–24.61; p = 0.00015). In these patients, GRP94 overexpression also increased the 
risk of BrM (HR = 3.58; 95% CI: 0.98–13.11; p = 0.054—Wald test). Therefore, FN14 
expression in Luminal breast carcinomas is a predictive/prognostic biomarker of BrM, 
which combined with GRP94 predicts BrM progression in non-Luminal tumors 4.04-fold 
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(1.19–8.22, p = 0.025), suggesting that both biomarkers are useful to stratify BrM risk at 
early diagnosis. We propose a new follow-up protocol for the early prevention of clinical 
BrM of breast cancer patients with BrM risk.
Keywords: biomarkers, brain metastasis, breast cancer, Fn14, grP94, prediction, prevention, prognosis
inTrODUcTiOn
Identification of molecular subtypes has enhanced our under-
standing of breast cancer biology (1), overcoming one of the main 
barriers to improving the progression, prognosis, and treatment 
of breast cancer, namely, its clinical and genetic heterogeneity. The 
gene expression patterns derived from cDNA microarrays of pri-
mary breast carcinomas have made it possible to correlate tumor 
characteristics with clinical outcome (2) and support the idea that 
breast tumor subtypes represent biologically distinct disease enti-
ties with different survival rates (3). The main recognized breast 
cancer subtypes are as follows: Luminal A, estrogen-receptor 
(ER) positive, Ki-67 <  14%, and normal expression of Her2; 
Luminal B, ER-positive, Ki-67 ≥  14%, and normal expression 
of Her2; Luminal/Her2+, ER-positive and Her2 overexpression; 
Her2-enriched, ER-negative and Her2 overexpression; and triple 
negative (TN), ER-negative, progesterone receptor (PR) negative, 
and normal expression of Her2. One of the important differences 
between subtypes as regards clinical progression is that hormone 
receptor-positive tumors, such as Luminal A, have a better 
prognosis for survival compared with Her2 overexpression and 
TN subtypes (4, 5) and the lowest risk of lymph node metastasis, 
whereas the Luminal-Her2+ subtype has the highest risk (6). 
Moreover, hormone receptor-positive subtypes such as Luminal 
A and Luminal B should be considered different oncologic enti-
ties sharing similarities when studying their pattern of response 
to therapy (7). Breast cancer molecular subtypes are used to 
stratify patients at increased risk of recurrence, who may benefit 
from more aggressive local treatment (8–10). For example, the 
Luminal/Her2+ and Her2-enriched subtypes are associated with 
a significantly higher rate of brain, lung, and liver metastases in 
comparison with the Luminal A subtype, whereas TN patients 
are associated with a higher rate of brain, lung and distant nodal 
metastases (11–14).
Despite improvements in diagnosis and novel adjuvant 
therapies, brain metastasis (BrM) is becoming a serious clinical 
problem, with a higher incidence in patients with histological 
grade (HG) 3, high Ki-67 expression (15), age younger than 
50  years old (11, 16), ER-negative and Her2-positive (11, 17). 
Breast cancer subtypes also determine the prognosis and survival 
of a patient with BrM (18, 19). Patients with Luminal tumors have 
a better survival rate than those with TN tumors (20), whereas 
those with the Her2-enriched subtype have a significantly poorer 
prognosis than those with Luminal/Her2+ or Luminal tumors 
(21). Patients with TN tumors have worse overall and disease-free 
survival rates (22), especially in patients with lung metastases. 
Even patients with non-metastatic TN breast cancer have a high 
early risk of developing BrM as a first site of recurrence (23), and 
worse survival after brain radiotherapy (24) than those with the 
non-TN phenotype. In these patients, BrM represents a significant 
adverse prognostic factor not only to overall survival but also to 
neurologic and radiosurgical survival (25).
We recently reported BrM biomarkers that discriminate 
breast carcinomas according to their likelihood of BrM progres-
sion, regardless of whether or not they expressed Her2 (26, 27). 
Of these, GRP94 (94 kDa glucose-regulated protein), a signaling 
regulator and a major endoplasmic reticulum chaperone and 
FN14 (fibroblast growth factor-inducible protein) implicated in 
many intracellular signaling pathways, both have been implicated 
in the promotion of tumor proliferation and metastasis.
GRP94 has calcium binding properties that are conferring 
its major function in protein folding, assembly and degradation 
(28, 29). Tumor hypoxia activates endoplasmic reticulum stress 
upregulating the unfolded protein response (30). The expression 
of GRP94 correlates with advanced stage and poor survival in 
many cancers (31, 32).
In addition, FN14 is implicated in several signaling path-
ways that control the cancer hallmarks (33). Typically, reactive 
astrocytes produce proinflammatory cytokines, among them 
TWEAK (TNF-like weak inducer of apoptosis), a type II mem-
brane protein which activates FN14 (34). The binding of TWEAK 
to FN14 is involved in regulating perivascular astrocytes and the 
blood–brain barrier interface (35). Moreover, FN14 has been 
involved in cachexia and the treatment with anti-FN14 antibod-
ies improves body and muscle mass and adipose tissue in mice, 
increasing survival and general welfare (36).
Given these results, we hypothesized that the expression of 
FN14 and GRP94 could be used for early identification of the 
risk of breast cancer brain metastasis, whatever the molecular 
subtype. Thus, we studied their expression in breast cancer 
primary tumors according to their molecular subtype defined 
by Her2, ER, PR, and Ki-67 expression. Our results indicate that 
FN14 is the most useful predictive/prognostic biomarker of BrM 
in breast cancer patients with Luminal (Luminal A, Luminal B, 
and Luminal/Her2+) carcinomas. Moreover, in combination with 
GRP94, FN14 predicts also BrM progression in non-Luminal 
tumors.
MaTerials anD MeThODs
Patients
We obtained 211 samples from patients diagnosed between 
1989 and 2009 (Table S1 in Supplementary Material) at the 
Abbreviations: BrM, brain metastasis; ER, estrogen receptor; PR, progesterone 
receptor; TN, triple negative; BCBrM, breast cancer brain metastasis; BrMFS, 
brain metastasis-free survival; NBrM, non-brain distant metastases; WoM, without 
metastases; NBrWoM, non-brain distant metastases and without metastases; HG, 
histological grade.
GRP94
FN14
NEGATIVE WEAK (-) HIGH (+)
OVER-EXPRESSION
FigUre 1 | Representative tabulation of protein expression in breast cancer samples. Representative staining of GRP94 and FN14 and tabulation of protein 
expression in breast cancer samples. Tissues are shown as viewed by light microscopy. Negative and weak intensities of staining were considered both negative  
for semi-quantitative purposes to avoid false positive samples, and only tumors with unequivocal high intensity staining were considered as positive overexpression. 
Original magnification 10×. Insets: standard positive control tissue sample used in each determination.
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following institutions: Catalan Institute of Oncology (I.C.O.), 
Hospital Duran i Reynals and the Hospital Universitari 
de Bellvitge (L’Hospitalet de Llobregat, Spain); Consorci 
Hospitalari Parc Taulí (Sabadell, Spain); and I.C.O., Hospital 
Universitari Germans Trias i Pujol (Badalona, Spain). A final 
total of 208 patients were included in this study, whose clinical 
(Table S2 in Supplementary Material), pathological param-
eters and molecular subtype status were as follows (Table S3 
in Supplementary Material): 40.3% Luminal A (ER-positive, 
Ki-67 <  14%); 18.5% Luminal B (ER-positive, Ki-67 ≥  14%); 
9.0% Luminal/Her2+ (ER-positive and Her2 overexpressed), 
10.0% Her2-enriched (ER-negative and Her2 overexpressed), 
and 22.2% TN tumors (ER-negative, PR-negative, and normal 
expression of Her2). Some missing values from these variables 
discarded three patients, two from Luminal tumors and one 
from non-Luminal tumors.
For this work involving databases of human information we 
followed the Spanish National law on the protection of Personal 
Data “Ley 15/1999, 13 Dec.”
histology and immunohistochemistry
Tissue microarrays (TMAs) were prepared from three repre-
sentative areas of the tumor, as described previously (27). Primary 
antibodies anti-GRP94 at 1/2,000 and anti-FN14 at 1/3,000 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) were diluted in 
Dako Real™ Antibody Diluent Buffer (Dakocytomation, Dako, 
Denmark): Tris buffer, pH 7.2, 15 mM Na3N. LSAB + System-
HRP (Dakocytomation) was used for staining, including second-
ary antibodies in PBS, streptavidin conjugated to HRP in PBS, 
and liquid 3,3′ diaminobenzidine in chromogen solution.
The overexpression of GRP94 and FN14 was categorized as 
positive when strong expression was detected and negative when 
no or weak expression was detected, to avoid false positives 
(Figure 1). Morphologic diagnosis was performed with classical 
hematoxylin–eosin staining.
statistics
Frequencies of categorical variables were compared among 
groups using the χ2-test or Fisher’s exact test where appropriate. 
Brain metastasis-free survival (BrMFS) was estimated for each 
group using the Kaplan–Meier method and was compared among 
them using the Cox proportional hazards model, estimating their 
hazard ratio and 95% CI.
To evaluate the correlation between BrM and protein expres-
sion, immunostained samples were graded on a three-category 
scale as follows: negative, weak positive, and strong positive. 
The marker was classified as overexpressed only in strong posi-
tive samples to avoid false positives. Biomarker sensitivity and 
specificity, both singly and in combination, was assessed in both 
Luminal and non-Luminal patients. The biomarkers combinations 
were considered positive when at least one of them was positive 
and negative when all of them were negative.
A multivariate logistic regression analysis adjusted for covari-
ates was carried out in both Luminal and non-Luminal groups to 
study in patients with BrM vs. NBrM the presence of biomarkers 
(GRP94 and FN14) in their primary tumor. The covariates used 
were as follows: age (≥50, 40–49, and <40), positive axillary 
nodes (0, 1–3, and ≥4), Her2 status (negative and positive), and 
presence of lung metastasis (no and yes), where the first category 
mentioned for each variable was the reference. We calculated the 
OR associated with the biomarker, its 95% CI and p-value.
In this analysis, the variable “triple negative (no, yes)” was 
not included as a covariate because all patients belonging to 
the Luminal group were “no” for this variable. Moreover, Her2 
status was not included as a covariate when the combination 
(GRP94 + FN14 + Her2) was used as the biomarker.
TaBle 1 | Distribution of patients with brain metastasis, other metastases 
(NBrM), and non-metastasis (without metastases) according to molecular 
subtype of the primary breast tumor.
Patients (N = 208)a
characteristics Brain 
metastases
non-brain 
distant 
metastases
Without 
metastases
p-Value 
(χ2-test)
N (%) N (%) N (%)
52 (25.0) 34 (16.3) 122 (58.7)
Molecular subtypes
Triple negative 27 (51.9) 7 (20.6) 12 (9.8)
Her2-enriched 12 (23.1) 3 (8.8) 6 (4.9)
Lum/Her2+ 6 (11.5) 3 (8.8) 10 (8.2)
Luminal B 5 (9.6) 8 (23.6) 25 (20.5)
Luminal A 2 (3.9) 13 (38.2) 69 (56.6) <0.0001
aPatients included in these three categories (N = 208/211). Three patients were missing 
(not suitable for biomarkers assessment).
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Values were considered significant when p was less than 0.05. 
Software used: R Core Team (37).
resUlTs
clinical characteristics of Breast 
carcinoma subtypes and BrM involvement
We studied patient characteristics according to three different 
groups of progression patterns (Table S1 in Supplementary 
Material): brain metastases (BrM), with or without metastases 
(WoM) at other sites; non-brain distant metastases (NBrM), 
patients with metastasis in bones and/or liver and/or lungs and/
or non-regional lymph nodes, but not in brain; and patients 
WoM. The distribution of breast cancer molecular subtypes 
changed across the three groups of patients. The main distinc-
tive parameters that characterized the BrM group were age, 
whereby below 50  years old was significantly different 
(p = 0.001); hormone receptor negativity [both ER (p < 0.0001) 
and PR (p <  0.0001)], an attribute of tumors that developed 
BrM in contrast to tumors from NBrM and WoM patients; and 
Her2 positivity and a high Ki-67 index (p = 0.01 and p < 0.0001, 
respectively). Other parameters, such as tumor size (p = 0.001), 
HG (p < 0.0001), and lymph node involvement (p < 0.0001) were 
similar among BrM and NBrM patients, but different in WoM 
patients.
More than 50% of BrM patients had TN tumors. By contrast, 
only 20.6% of NBrM and 9.8% of WoM patients had TN tumors 
(χ2-test: p < 0.0001). Important differences were observed in the 
Her2-enriched subtype with regard to metastasis progression, 
occurring in 23.1% of BrM, 8.8% of NBrM, and 4.9% of WoM 
groups. Moreover, the distribution of Luminal/Her2+ tumors 
was different in patients according metastasis involvement, 
being 11.5% in BrM, 8.8% in NBrM, and 8.2% in WoM groups. 
Therefore, according to the clinical and pathological character-
istics of breast cancer patients, we established two main groups 
due to limited size of our sample: the Luminal group (Luminal A, 
Luminal B, and Luminal/Her2+ subtypes), which encompassed 
25% (13/52) of patients with BrM, 70.6% (24/34) with NBrM 
and 85.3% (104/122) of WoM patients; and the non-Luminal 
group (TN and Her2-enriched subtypes), encompassing 75% 
(39/52) of patients with BrM, 29.4% (10/34) with NBrM, and 
14.7% (18/122) of WoM patients. The clinical and pathological 
parameters of the Luminal and non-Luminal groups are described 
in Supplementary Table S4 in Supplementary Material: tumor 
size, ≥21 mm in 32.61 vs. 55.56%, respectively (p = 0.002); HG 3, 
32.12 and 81.25%, respectively (p < 0.0001); and regional lymph 
node involvement (affected ≥4), in 14.39 vs. 35.39%, respectively 
(p = 0.0008).
As expected, significant differences were related to the thera-
peutic approach adopted: 81.82% of Luminal patients vs. 58.21% of 
non-Luminal patients did not receive neoadjuvant chemotherapy 
(p = 0.0002); 83.22 vs. 55.88% (p < 0.0001) received conservative 
surgery; 44.76 vs. 18.03% (p =  0.001) did not receive adjuvant 
chemotherapy; and 85.92 vs. 6.06% (p < 0.0001) received tamox-
ifen or another antiestrogen as hormonal therapy, respectively. 
Moreover, clinical relapses, with the presence of local (8.39 vs. 
19.12%, p =  0.024), regional (1.40 vs. 16.18%, p <  0.0001), or 
distant relapses (27.27 vs. 73.53%, p < 0.0001) were less frequent 
in patients from the Luminal group than in those in the non-
Luminal group, respectively.
The incidence of BrM (Table 1) was significantly higher in the 
non-Luminal group than in the Luminal group [58.21% (39/67) 
vs. 9.22% (13/141), p < 0.0001]. Furthermore, patient outcomes 
corroborated the clinical and pathological characteristics, with an 
increase in metastasis-free survival when tumors were Luminal in 
both BrM and NBrWoM groups (Figures S1A,B in Supplementary 
Material). Moreover, the worst prognosis was found in patients 
with non-Luminal tumors (HR = 10.57, 95% CI: 5.60–19.96; and 
HR = 4.01, 95% CI: 2.52–6.38; respectively, p < 0.0001). These 
results indicate that the assessment of subtypes in our series pro-
vided an effective subclassification according to BrM progression 
in patients, similar to other reported series (11, 14).
Fn14 and grP94 stratify Breast cancer 
Molecular subtypes according to Their 
BrM Progression risk
Since molecular subtypes in NBrM (tumors with bone, liver, 
lung, skin, etc.) and WoM had a similar clinic-pathological 
parameters distribution (Fisher’s exact test, p  =  0.230; data 
not shown), we considered both as a single group (NBrWoM) 
to better compare the expression of BrM biomarkers between 
Luminal (N  =  141) and non-Luminal (N  =  67) tumors (see 
Table 2). FN14 was overexpressed in 14.5% (20/138) of Luminal 
tumors and in 23.1% (15/65) of non-Luminal tumors. Moreover, 
in Luminal tumors, FN14 expression was significantly different 
between the BrM and NBrWoM groups, at 53.8% (7/13) vs. 
10.4% (13/125), respectively (Fisher’s exact test, p  =  0.0005). 
FN14 expression in non-Luminal tumors differed between 
BrM and NBrWoM patients, being 31.6% (12/38) vs. 11.1% 
(3/27), respectively, although not significantly (Fisher’s exact 
test, p =  0.07). Therefore, we concluded that FN14 expression 
in Luminal breast tumors was associated with BrM progression. 
TaBle 2 | Distribution of biomarkers in brain metastasis (BrM) and NBrWoM 
patients in both Luminal and non-Luminal groups.
Patients (N = 208)
Biomarker luminal group (N = 141) non-luminal group 
(N = 67)
BrM nBrWoMa BrM nBrWoMa
N (%) N (%) N (%) N (%)
FN14+b 7/13 (53.8) 13/125 (10.4) 12/38 (31.6) 3/27 (11.1)
Fisher’s exact test (p = 0.0005) Fisher’s exact test (p = 0.07)
GRP94+c 10/13 (76.9) 56/126 (44.4) 22/38 (57.9) 11/28 (39.3)
Fisher’s exact test (p = 0.04) Fisher’s exact test (p = 0.21)
aThis category encompasses those patients “without metastases” and those with  
“non-brain distant metastases” [bone, lung, liver, and non-regional lymph node 
metastases; in this category, five patients were previously excluded because they only 
had skin metastasis (n = 2), pleural metastasis (n = 2), or meningeal metastasis (n = 1)].
bFN14 biomarker was assessed in 138 patients belonging to the Luminal group  
(this was not possible in 3 of them) and in 65 from the non-Luminal group (this was not 
possible in 2 of them).
cGRP94 biomarker was assessed in 139 patients belonging to the Luminal group 
(this was not possible in 2 of them) and in 66 from the non-Luminal one (this was not 
possible for 1 of them).
Differences shown in number of patients (N) in each group are due to patients whose 
biomarkers were not available.
5
Martínez-Aranda et al. Prediction of BCBrM
Frontiers in Oncology | www.frontiersin.org December 2017 | Volume 7 | Article 283
GRP94 was overexpressed in 47.5% (66/139) of Luminal and 
50% (33/66) of non-Luminal tumors. Biomarkers expression in 
Luminal tumors was also significantly different between BrM 
and NBrWoM patients, being 76.9% (10/13) vs. 44.4% (56/126) 
(Fisher’s exact test; p  =  0.04), whereas GRP94 expression in 
the non-Luminal group was similar for BrM, at 57.9% (22/38) 
of patients, and NBrWoM at 39.3% (11/28) (Fisher’s exact 
test; p  =  0.21). These results highlight the intrinsic value of 
FN14 and GRP94 as organ-specific BrM biomarkers mainly in 
patients with tumors from the Luminal subtype.
Furthermore, we analyzed in tumors with BrM progression 
if the expression of BrM biomarkers were associated with Her2 
overexpression. We found that FN14 expression was independ-
ent of Her2 status in patients with BrM from the Luminal group 
(Fisher’s exact test; p =  0.59). By contrast, FN14 expression in 
the non-Luminal group was associated in 63.6% of cases with the 
Her2-enriched subtype (Table S5 in Supplementary Material), dif-
fering from TN tumors, of which 18.5% were positive for FN14 
(Fisher’s exact test, p = 0.017).
GRP94 expression in tumors from BrM affected patients 
was independent of Her2 status (Table S5 in Supplementary 
Material) in the Luminal (Fisher’s exact test; p  =  1.00) and 
non-Luminal groups (Fisher’s exact test, p = 0.30).
Fn14 and grP94 are Prognostic 
Biomarkers for BrM in luminal Tumors
First, we studied metastasis-free survival in our series according 
to molecular subtype (Figure S2 in Supplementary Material), 
using the Kaplan–Meier method and the Cox proportional 
hazards model. The TN subtype was used as a reference group 
for comparative purposes. We analyzed the distribution of 
subtypes in NBrM patients (Figure S2A in Supplementary 
Material). Differences between the TN and Her2-enriched 
subtypes were not statistically significant (HR = 0.81; 95% CI: 
0.41–1.60; p = 0.53). By contrast, Luminal/Her2+ (HR = 0.41; 
95% CI: 0.18–0.96; p = 0.039), Luminal B (HR = 0.33; 95% CI: 
0.17–0.64; p =  0.0012), and Luminal A (HR =  0.16; 95% CI: 
0.08–0.30; p < 0.0001) showed a significantly lower incidence 
of NBrM than TN breast carcinomas. Furthermore, in BrM 
patients, we found significant differences in BrMFS with regard 
to molecular subtype, using the TN subtype as the reference 
group (Figure S2B in Supplementary Material): Her2-enriched 
did not differ significantly from TN (HR  =  0.79; 95% CI: 
0.40–1.55; p  =  0.49), but the remaining subtypes showed a 
significantly lower risk than TN: Luminal/Her2+: HR = 0.33; 
95% CI: 0.13–0.80; p = 0.014. Luminal B: HR = 0.13; 95% CI: 
0.05–0.33; p <  0.0001 and Luminal A: HR =  0.02; 95% CI: 
0.005–0.09; p < 0.0001.
Next, we studied BrMFS in the Luminal group according to 
whether the tumor expressed FN14 or not (Figure 2A), and we 
found that overexpression of FN14 was associated with a reduc-
tion in BrMFS (HR =  8.25; 95% CI: 2.77–24.61; p =  0.00015). 
Although, different stratification of the non-Luminal group 
(Figure 2B) according to FN14 expression was not statistically 
significant (HR = 1.74; 95% CI: 0.87–3.47; p = 0.11).
In addition, we analyzed BrMFS in the Luminal group 
according to GRP94 expression (Figure 2C) and observed that 
GRP94 was overexpressed in tumors from patients with reduced 
BrMFS (HR  =  3.58; 95% CI: 0.98–13.11; p  =  0.054—Wald 
test), although this finding did not reach statistical significance 
either. Meanwhile, BrMFS according to GRP94 expression in 
non-Luminal tumors was not significantly different (HR = 1.22; 
95% CI: 0.64–2.32; p = 0.55) (Figure 2D).
Fn14 is a Predictive Biomarker of BrM  
in luminal Tumors
Since overexpression of the Her2 gene is associated with a higher 
risk to develop BrM, we analyzed the sensitivity and specificity 
of FN14 and GRP94 expression to predict BrM and compared 
these parameters to the prediction given by Her2 in these patients 
(Table 3). In patients belonging to the Luminal group (low risk of 
BrM a priori), FN14 and Her2 showed more specificity (89.60 and 
89.84%, respectively) than GRP94 (55.56%) to predict BrM pro-
gression. However, GRP94 expression showed more sensitivity 
(76.92%) than FN14 and Her2 (53.85 and 46.15%, respectively) 
to predict BrM involvement.
On the other hand, in patients with a higher risk of BrM, 
such as non-Luminal ones, FN14 (88.89%) was the most specific 
protein to discriminate tumors that developed BrM, followed 
by Her2 (67.86%) and GRP94 (60.71%). GRP94 sensitivity was 
again higher (57.89%) than that obtained with FN14 or Her2 
(31.58 and 30.77%, respectively).
Expression of the biomarker combination FN14 +  GRP94 
improved BrM risk assessment in Luminal patients compared 
with non-Luminal ones (sensitivity: 84.62 and 68.42%, specific-
ity: 50 and 57.14%, respectively). The addition of Her2 yielded 
84.62 and 71.79% sensitivity, and 45.24 and 42.86% specificity in 
Luminal with regard to non-Luminal, respectively (Table 3). The 
TaBle 3 | Sensitivity and specificity of biomarkers, singly or in combination, with regard to brain metastases in Luminal and non-Luminal patients.
Patients (N = 208)
Biomarker luminal group (N = 141) non-luminal group (N = 67)
Nb sensitivity (%) specificity (%) Nb sensitivity (%) specificity (%)
FN14 138 (53.85) (89.60) 65 (31.58) (88.89)
GRP94 139 (76.92) (55.56) 66 (57.89) (60.71)
Her2 141 (46.15) (89.84) 67 (30.77) (67.86)
FN14 + GRP94a 139 (84.62) (50.00) 66 (68.42) (57.14)
FN14 + GRP94 + Her2a 139 (84.62) (45.24) 67 (71.79) (42.86)
aIn each case, these combinations were considered positive when at least one of the assessed molecules was positive and negative when all of them were negative.
bDifferences in number or patients (N) are due to those patients whose biomarker assessment (singly or in combination) was unknown.
A C
B D
FigUre 2 | Brain metastasis-free survival (BrMFS) in breast cancer patients according to expression of FN14 and GRP94 biomarkers. Comparisons between 
Luminal (a) and non-Luminal (B) groups, according to FN14 positivity in primary tumors revealed a shortened BrMFS that was statistically significant in the Luminal 
group (HR = 8.25; 95% CI: 2.77–24.61; p = 0.00015) but not in the non-Luminal one (HR = 1.74; 95% CI: 0.87–3.47; p = 0.11). With regard to GRP94 positivity, 
shortened BrMFS in Luminal (c) and non-Luminal (D) groups was not statistically significant (HR = 3.58; 95% CI: 0.98–13.11; p = 0.054 and HR = 1.22; 95%  
CI: 0.64–2.32; p = 0.55, respectively).
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combination of FN14 + GRP94 + Her2 increased sensitivity to 
predict BrM in both Luminal and non-Luminal cases, covering a 
wide range of patients.
The high specificity shown by FN14 and Her2 when evaluated 
singly was lost in combination, suggesting that both biomarkers 
stratified different patient subgroups of BrM risk.
To assess the usefulness of FN14 and GRP94 as independ-
ent risk factors of BrM, a multivariate analysis was performed, 
including age, axillary node involvement, Her2 status, and pres-
ence of lung metastasis as covariates in the analysis (Table 4).
Outcomes showed that patients belonging to the Luminal 
group (ER+) had a statistically significant higher risk to develop 
BrM if the tumor expressed FN14 compared with those with FN14 
negative tumors (OR: 36.70; 95% CI: 3.65–368.25; p =  0.002). 
The likelihood of these patients to develop BrM increased 
36.70-fold. By contrast, when tumors overexpressed GRP94, the 
risk to develop BrM (OR = 5.74; 95% CI: 0.87–37.66) remained 
non-significant (p =  0.069), either in combination with FN14 
(p =  0.066) or Her2 (p =  0.071) positivity (OR =  7.10, 95% 
CI: 0.88–57.51; and OR = 5.80, 95% CI: 0.86–39.08, respectively).
TaBle 4 | Multivariate analysis of biomarkers in patients with brain metastasis 
from the Luminal and non-Luminal groups.
Patients (N = 199)a
Biomarker luminal group  
(N = 136)
non-luminal group 
(N = 63)
Or (95% ci) p Or (95% ci) p
FN14 36.70 (3.65–368.25) 0.002 3.29 (0.64–16.79) 0.153
GRP94 5.74 (0.87–37.66) 0.069 3.23 (0.98–10.63) 0.053
FN14 + GRP94b 7.10 (0.88–57.51) 0.066 4.04 (1.19–13.65) 0.025
FN14 + GRP94 + Her2b 5.80 (0.86–39.08) 0.071 2.45 (0.73–8.22) 0.147
The covariates used in this study were as follows: age, axillary lymph node involvement, 
Her2 status, and presence of lung metastasis. Her2 was not included as a covariate 
when we used the combination GRP94 + FN14 + Her2 as biomarker.
aThe number of patients (N) obtained in each group corresponds to those patients who 
presented all the required covariates.
bIn each case, these combinations were considered positive when at least one of the 
assessed molecules was positive and negative when all of them were negative.
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In non-Luminal patients, only the combination of FN14 and 
GRP94 positivity was significantly predictive of BrM progres-
sion (95% CI: 1.19–13.65, p = 0.025), with a 4.04-fold likelihood 
to develop BrM (Table 4). These results are in consonance with 
our previous results reporting the usefulness of both biomarkers 
to predict BrM in TN breast cancer patients (27).
In summary, our study reveals that (1) A subset of breast 
cancer patients with a better prognosis a priori, such as estro-
gen-receptor positive with or without Her2 positivity, develop 
brain metastases if FN14 and/or GRP94 biomarkers are positive 
in their primary tumor. (2) FN14-positive status impairs the 
prognosis of breast cancer patients by shortening the length 
of BrMFS. (3) The likelihood to develop BrM in patients with 
FN14-positive tumors increases 36.70-fold (p = 0.002). (4) The 
combined assessment of biomarkers (FN14 + GRP94) shows a 
higher benefit in risk evaluation of BrM in patients with non-
Luminal tumors.
Since stratification impairs statistical consistency, further 
multicentre studies with wider amount of patients are needed to 
reinforce the results.
DiscUssiOn
The routine analysis of ER, PR, Ki-67, and Her2 status in 
breast tumors can predict relapse, providing the standard 
approach for clinical decision-making in the adjuvant set-
ting (17–19). However, these procedures are insufficient to 
predict BrM.
This study provides evidence that a subset of breast cancer 
patients with a better prognosis a  priori, such as patients with 
Luminal carcinomas, with or without Her2 positivity, can be 
stratified by their likelihood to develop BrM if FN14 is overex-
pressed (OR = 36.70). Thus, the clinical use of FN14 expression 
might facilitate a preventive strategy for patients at high risk for 
BrM progression and will improve the design of trials aimed at 
its prevention. Moreover, the combined assessment of both FN14 
and GRP94 proteins shows a higher benefit in risk evaluation of 
BrM progression, especially in non-Luminal patients (4.04-fold), 
independently of Her2 status (OR = 2.45). Therefore, the use of 
FN14 and GRP94 expression at early diagnosis might stratify 
those BrM patients prone to BrM.
Many studies have reported risk factors for BrM, including 
Her2 positivity, ER negativity, high proliferative activity, young 
age and lymph node involvement (38, 39). FN14 and GRP94 
comprise a diagnostic tool capable of predicting BrM indepen-
dently of these classical clinical and pathological parameters. The 
long-term BrM-free survival of Luminal group patients when 
biomarkers are negative suggests the usefulness of including both 
biomarkers to stratify patients that might benefit from magnetic 
resonance imaging (MRI-Gd) follow-up. This should be consid-
ered for at least 7 years (about 80 months) after diagnosis, the 
period after which BrM relapse in the Luminal group stabilizes 
(Figure 2). Therefore, we suggest that intrinsic subtypes of breast 
cancer plus FN14 and GRP94 expression can provide a reli-
able assessment of BrM risk, facilitating early diagnosis through 
follow-up of the patient’s evolution (Figure 3). Even patients from 
the non-Luminal group could benefit from stratification using 
FN14 and GRP94 biomarkers. This is not surprising because in 
combination, they are good predictors of BrM progression in 
TN breast carcinomas (27). Consequently, if these findings were 
confirmed in further studies, it would also enable us to apply a 
specific clinical and therapeutical algorithm to improve breast 
cancer patients’ follow-up.
Although the armamentarium available for BrM treatment 
is limited, there are reasons to be optimistic because emerging 
therapies have shown promise in preclinical and early clinical 
settings (40–42). Moreover, a protocol that included an MRI 
procedure might provide indications for early surgery and/or 
radiosurgery when BrM is small to minimal and/or for the design 
of a new approach in prophylactic systemic protocols (e.g., to 
replace or add another drug and/or biological compound that 
crosses the blood–brain barrier to avoid the growth of a clinical 
BrM) as well as for the design of a new protocol as a prophylactic 
approach.
Patients with Her2 positivity in primary tumor are usu-
ally treated with trastuzumab after delivering chemotherapy, 
obtaining a better systemic response (43). In our series, 99% of 
patients did not receive trastuzumab as adjuvant therapy. Thus, an 
interesting approach would be to study the relationship between 
FN14 and GRP94 expression and BMFS in those patients 
belonging to the Lum/Her2+ and Her2-enriched subtypes who 
have received trastuzumab. In our multicenter series, GRP94 
and FN14 expression might improve breast cancer survival by 
predicting BrM. In particular, FN14 has a similar sensitivity and 
specificity to that of Her2.
Immunophenotypic changes associated with antitumor 
activity have been observed with anti-TWEAK antibody 
treatment in mice and a phase I multicenter trial of RG7212 
monotherapy in patients with FN14-expressing advanced solid 
tumors has been initiated, with good tolerability and favorable 
pharmacokinetics (44). Therefore, these molecules might be 
good candidates to develop new drugs to treat or prevent 
BrM according to the tumor-associated risk of breast cancer 
patients.
FigUre 3 | Proposed protocol from diagnosis to prophylaxis and/or treatment approach for patients at risk of brain metastasis. Black: current diagnosis protocol. 
Blue: proposed follow-up approach for those patients from the Luminal group expressing positive biomarkers. Green: prophylaxis and therapies based on biomarker 
expression.
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In itself, BrM is an exclusion criterion for most prospective 
trials, limiting the possibility of developing new therapies (45). 
Moreover, therapies are usually started when symptoms appear, 
limiting treatment options and success (41). We propose a new 
classification that provides a standard approach for clinical 
decision-making about CNS metastases at early diagnosis when 
adjuvant chemotherapy and radiosurgery are more effective (46). 
Furthermore, evaluation of new and more specific biomarkers in 
primary tumor may be a promising field of research due to the 
high impact that these might have in the future as regards facili-
tating the design of new therapeutic strategies to either prevent 
or treat this life-threatening event.
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